ARTICLE | Company News

Stallergenes, Ares Life Sciences, Wendel inflammation news

November 8, 2010 8:00 AM UTC

Fellow investment firm Ares proposed to acquire Wendel's 45.87% interest in Stallergenes for €358.8 million ($501.3 million), or €59 per share. The price is a 9% discount to Stallergenes' close of €64.50 on Oct. 28 before the announcement. Wendel said it would generate about 35 times its investment. ...